Clinical Trial Update: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the addition of a telomerase-derived CD4 Th1-inducer cancer vaccine to atezolizumab plus bevacizumab in unresectable hepatocellular car…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• Telomerase-derived CD4 Th1-inducer cancer vaccine

Snippet

Sponsor: Centre Hospitalier Universitaire de Besancon | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: RECRUITING